Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | NCF1 | P14598 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803675 | 0.85 | HSD17B10 (0.46) | KDM4ECYP1A2HSD17B10 | |
| SCHEMBL7835747 | 0.84 | HSD17B10 (0.49) | KDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL497431 | 0.81 | DCTPP1 (0.48) | ALDH1A1HSD17B10 | |
| SCHEMBL24127173 | 0.74 | ACHE (0.43) | ALDH1A1 | |
| SCHEMBL14921731 | 0.73 | MEN1 (0.36) | HSD17B10 | |
| SCHEMBL20606156 | 0.70 | KMT2A (0.41) | KDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL3096843 | 0.69 | KDM4E (0.48) | HRH3PLD1ADRB2NCF1KDM4E | |
| SCHEMBL18075521 | 0.69 | MEN1 (0.37) | ALDH1A1 | |
| SCHEMBL8809712 | 0.69 | MAPT (0.60) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL4456263 | 0.68 | KDM4E (0.47) | HRH3PLD1ADRB2NCF1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105814043-B | Triazolopyridine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-105814049-B | Fused tricyclic imdazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-105814041-B | Benzotriazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-105814065-B | Imidazothiazole derivative as TNF active regulator | UCB生物制药私人有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105814058-B | Triazolo-pyridazine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-105814047-B | Fused tricyclic imdazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-105814022-B | Condensed bicyclic heteroaromatic derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105814051-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-105814054-B | Condensed imidazole and pyrazole derivatives as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-25 | — | — | CN | disclosed |
| CN-105814025-B | Tetrahydrobenzimidazderivative derivative as TNF active regulators | UCB生物制药私人有限公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-105814022-A | Fused bicyclic heteroaromatic derivatives as modulators of tnf activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814048-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814045-A | Imidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-105814055-A | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| EP-2033963-B1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2011-02-16 | — | — | EP | disclosed |
| US-20090281083-A1 | Combination Product | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| EP-1603910-B1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1874774-A1 | COMBINATION PRODUCT | AstraZeneca AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006112772-A1 | COMBINATION PRODUCT | ASTRAZENECA AB (SE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1136483-A1 | 2-[Piperazinyl]pyrimidone derivatives | SANOFI-SYNTHELABO (FR) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281083-A1 | Combination Product | PAH, PTGIS, CYP11B2 | HRH3 302/4885PLD1 2688/4885ADRB2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.